Could Aduhelm Be Taken Off Market If CMS Proposal Stands? ‘Everything Is On The Table,’ Biogen Says
Executive Summary
Company execs say there has been four-fold increase in doctors infusing the Alzheimer’s drug and despite lack of support from major institutions, individual physicians at Cleveland Clinic and elsewhere have voiced support for Aduhelm. Biogen is “cautiously optimistic” about lecanemab Phase III trial.
You may also be interested in...
Eisai Gives Full Aduhelm Responsibility To Biogen Under Amended Agreement
The companies amended the terms of their Alzheimer’s collaboration to give Biogen full decision-making control over Aduhelm immediately. Eisai’s 50% share of profits and losses from the drug switches to a 2% royalty in 2023. The partners’ agreement for Eisai-led lecanemab remains intact.
Lilly Waiting On Phase III Data For Donanemab
Lilly no longer plans to complete an accelerated approval submission for Alzheimer’s candidate donanemab during Q1 following the CMS draft coverage decision for amyloid-targeting therapies.
A Biopharma M&A Bonanza In 2022? Analysts Pick Top Targets And Likely Buyers
As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.